Brian Dennis Lichty

List of Publications by Year
in descending order

91	8,264	41344	49	49909	87
papers	citations		h-index		g-index

96	96	96	9013
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI Insight, 2022, 7, .	5.0	46
2	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell, 2022, 185, 896-915.e19.	28.9	189
3	Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression. , 2022, 10, e003923.		13
4	Probing effects of additives on the filterability of oncolytic viruses via a microfiltration process. Journal of Membrane Science, 2021, 620, 118783.	8.2	0
5	RNA editing enzyme APOBEC3A promotes pro-inflammatory M1 macrophage polarization. Communications Biology, 2021, 4, 102.	4.4	28
6	Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers. OncoImmunology, 2021, 10, 1885778.	4.6	12
7	CXCR6 by increasing retention of memory CD8⁺ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. , 2021, 9, e003329.		25
8	Spray dried VSV-vectored vaccine is thermally stable and immunologically active in vivo. Scientific Reports, 2020, 10, 13349.	3.3	11
9	Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning. , 2020, 8, e000981.		15
10	Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology, 2020, 20, 615-632.	22.7	806
11	Measles Vaccines Designed for Enhanced CD8+ T Cell Activation. Viruses, 2020, 12, 242.	3.3	15
12	Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination. Methods in Molecular Biology, 2020, 2058, 191-211.	0.9	7
13	Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. , 2019, 7, 189.		41
14	Purification of therapeutic adenoviruses using laterally-fed membrane chromatography. Journal of Membrane Science, 2019, 579, 351-358.	8.2	10
15	Excipient selection for thermally stable enveloped and non-enveloped viral vaccine platforms in dry powders. International Journal of Pharmaceutics, 2019, 561, 66-73.	5.2	22
16	Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. OncoImmunology, 2019, 8, e1512329.	4.6	53
17	Endogenous T cells prevent tumor immune escape following adoptive T cell therapy. Journal of Clinical Investigation, 2019, 129, 5400-5410.	8.2	76
18	Transforming the prostatic tumor microenvironment with oncolytic virotherapy. OncoImmunology, 2018, 7, e1445459.	4.6	26

#	Article	IF	Citations
19	Consecutive Spray Drying to Produce Coated Dry Powder Vaccines Suitable for Oral Administration. ACS Biomaterials Science and Engineering, 2018, 4, 1669-1678.	5.2	6
20	Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages. OncoImmunology, 2018, 7, e1423171.	4.6	26
21	Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Science Translational Medicine, 2018, 10, .	12.4	242
22	Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. Vaccine, 2018, 36, 2181-2192.	3.8	22
23	Sterile filtration of oncolytic viruses: An analysis of effects of membrane morphology on fouling and product recovery. Journal of Membrane Science, 2018, 548, 239-246.	8.2	20
24	Development and applications of oncolytic Maraba virus vaccines. Oncolytic Virotherapy, 2018, Volume 7, 117-128.	6.0	34
25	Customized Viral Immunotherapy for HPV-Associated Cancer. Cancer Immunology Research, 2017, 5, 847-859.	3.4	32
26	Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats. Scientific Reports, 2017, 7, 15738.	3.3	11
27	Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214.. Journal of Clinical Oncology, 2017, 35, e14637-e14637.	1.6	10
28	Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence. PLoS ONE, 2016, 11, e0155947.	2.5	68
29	Oncolytic Viruses: Therapeutics With an Identity Crisis. EBioMedicine, 2016, 9, 31-36.	6.1	82
30	Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination. Journal of Immunology, 2016, 196, 4587-4595.	0.8	35
31	S6K-STING interaction regulates cytosolic DNAâ€“mediated activation of the transcription factor IRF3. Nature Immunology, 2016, 17, 514-522.	14.5	67
32	Cancer immunology and canine malignant melanoma: A comparative review. Veterinary Immunology and Immunopathology, 2016, 169, 15-26.	1.2	62
33	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell, 2015, 28, 210-224.	16.8	77
34	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nature Medicine, 2015, 21, 530-536.	30.7	118
35	Microvesicles: ubiquitous contributors to infection and immunity. Journal of Leukocyte Biology, 2015, 97, 237-245.	3.3	54
36	Maraba MG1 Virus Enhances Natural Killer Cell Function via Conventional Dendritic Cells to Reduce Postoperative Metastatic Disease. Molecular Therapy, 2014, 22, 1320-1332.	8.2	60

#	Article	IF	Citations
37	Maraba Virus as a Potent Oncolytic Vaccine Vector. Molecular Therapy, 2014, 22, 420-429.	8.2	134
38	Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy. Molecular Therapy, 2014, 22, 123-131.	8.2	93
39	Human Coronavirus OC43 Nucleocapsid Protein Binds MicroRNA 9 and Potentiates NF-Î°B Activation. Journal of Virology, 2014, 88, 54-65.	3.4	66
40	Going viral with cancer immunotherapy. Nature Reviews Cancer, 2014, 14, 559-567.	28.4	500
41	Evolution of oncolytic viruses: novel strategies for cancer treatment. Immunotherapy, 2013, 5, 1191-1206.	2.0	49
42	HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy. Molecular Therapy, 2013, 21, 887-894.	8.2	98
43	Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy. Cancer Immunology Research, 2013, 1, 309-319.	3.4	62
44	Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8⁺T-cell responses to anticancer vaccines. OncoImmunology, 2013, 2, e26013.	4.6	51
45	Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8+ T-cell recall responses. Blood, 2013, 121, 2432-2439.	1.4	36
46	ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic. Molecular Therapy, 2012, 20, 1148-1157.	8.2	59
47	Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Therapy, 2012, 19, 238-246.	4.6	94
48	Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell Vaccine. Molecular Therapy, 2012, 20, 1791-1799.	8.2	70
49	IL-15 Can Signal via IL-15RÎ±, JNK, and NF-Î°B To Drive RANTES Production by Myeloid Cells. Journal of Immunology, 2012, 188, 4149-4157.	0.8	40
50	Strategies to Enhance Viral Penetration of Solid Tumors. Human Gene Therapy, 2011, 22, 1053-1060.	2.7	53
51	Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy. Molecular Therapy, 2011, 19, 335-344.	8.2	88
52	A critical role for ILâ€15 in TLRâ€mediated innate antiviral immunity against genital HSVâ€2 infection. Immunology and Cell Biology, 2011, 89, 663-669.	2.3	13
53	Targeting Tumor Vasculature With an Oncolytic Virus. Molecular Therapy, 2011, 19, 886-894.	8.2	149
54	Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood, 2011, 117, 2668-2680.	1.4	48

#	Article	IF	Citations
55	Vesicular Stomatitis Virus Oncolytic Treatment Interferes with Tumor-Associated Dendritic Cell Functions and Abrogates Tumor Antigen Presentation. Journal of Virology, 2011, 85, 12160-12169.	3.4	33
56	IL-15 and Type I Interferon Are Required for Activation of Tumoricidal NK Cells by Virus-Infected Dendritic Cells. Cancer Research, 2011, 71, 2497-2506.	0.9	49
57	Combining Oncolytic Viruses with Cancer Immunotherapy. , 2011, , 339-355.		0
58	Immunotherapy Can Reject Intracranial Tumor Cells without Damaging the Brain despite Sharing the Target Antigen. Journal of Immunology, 2010, 184, 4269-4275.	0.8	16
59	IL-15 has innate anti-tumor activity independent of NK and CD8 T cells. Journal of Leukocyte Biology, 2010, 88, 529-536.	3.3	23
60	FimH Can Directly Activate Human and Murine Natural Killer Cells via TLR4. Molecular Therapy, 2010, 18, 1379-1388.	8.2	65
61	A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers. Molecular Therapy, 2010, 18, 1123-1129.	8.2	85
62	Potentiating Cancer Immunotherapy Using an Oncolytic Virus. Molecular Therapy, 2010, 18, 1430-1439.	8.2	146
63	Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing. Molecular Therapy, 2010, 18, 888-895.	8.2	109
64	Combining oncolytic virotherapy and tumour vaccination. Cytokine and Growth Factor Reviews, 2010, 21, 143-148.	7.2	32
65	Intelligent Design: Combination Therapy With Oncolytic Viruses. Molecular Therapy, 2010, 18, 251-263.	8.2	177
66	The p14 FAST Protein of Reptilian Reovirus Increases Vesicular Stomatitis Virus Neuropathogenesis. Journal of Virology, 2009, 83, 552-561.	3.4	52
67	Recombinant Vesicular Stomatitis Virus Transduction of Dendritic Cells Enhances Their Ability to Prime Innate and Adaptive Antitumor Immunity. Molecular Therapy, 2009, 17, 1465-1472.	8.2	66
68	Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With Adenovirus. Molecular Therapy, 2009, 17, 1814-1821.	8.2	95
69	Diplomatic immunity: turning a foe into an ally. Current Opinion in Molecular Therapeutics, 2009, 11, 13-21.	2.8	18
70	Using G-deleted vesicular stomatitis virus to probe the innate anti-viral response. Journal of Virological Methods, 2008, 153, 276-279.	2.1	5
71	A let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumor-specific Replication. Molecular Therapy, 2008, 16, 1437-1443.	8.2	121
72	Heterologous Boosting of Recombinant Adenoviral Prime Immunization With a Novel Vesicular Stomatitis Virusâ€“vectored Tuberculosis Vaccine. Molecular Therapy, 2008, 16, 1161-1169.	8.2	40

#	Article	IF	Citations
73	Cigarette Smoke Suppresses Type I Interferon-Mediated Antiviral Immunity in Lung Fibroblast and Epithelial Cells. Journal of Interferon and Cytokine Research, 2008, 28, 167-179.	1.2	53
74	Cutting Edge: FimH Adhesin of Type 1 Fimbriae Is a Novel TLR4 Ligand. Journal of Immunology, 2008, 181, 6702-6706.	0.8	113
75	Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity. Molecular Therapy, 2007, 15, 123-130.	8.2	171
76	Mucosal Luminal Manipulation of T Cell Geography Switches on Protective Efficacy by Otherwise Ineffective Parenteral Genetic Immunization. Journal of Immunology, 2007, 178, 2387-2395.	0.8	81
77	Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis, 2006, 86, 211-217.	1.9	61
78	Cigarette Smoke Impacts Immune Inflammatory Responses to Influenza in Mice. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1342-1351.	5.6	91
79	Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV Î”M51) on Multifocal and Invasive Gliomas. Journal of the National Cancer Institute, 2006, 98, 1546-1557.	6.3	88
80	Induction of Innate Immunity against Herpes Simplex Virus Type 2 Infection via Local Delivery of Toll-Like Receptor Ligands Correlates with Beta Interferon Production. Journal of Virology, 2006, 80, 9943-9950.	3.4	90
81	Matrix protein of Vesicular stomatitis virus harbours a cryptic mitochondrial-targeting motif. Journal of General Virology, 2006, 87, 3379-3384.	2.9	18
82	Vesicular Stomatitis Virus: A Potential Therapeutic Virus for the Treatment of Hematologic Malignancy. Human Gene Therapy, 2004, 15, 821-831.	2.7	76
83	Vesicular stomatitis virus: re-inventing the bullet. Trends in Molecular Medicine, 2004, 10, 210-216.	6.7	278
84	VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell, 2003, 4, 263-275.	16.8	734
85	Exon-skipping in BCR/ABL is induced by ABL exon 2. Biochemical Journal, 2000, 348, 63.	3.7	3
86	Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Medicine, 2000, 6, 821-825.	30.7	742
87	The Murine Double-Stranded RNA-Dependent Protein Kinase PKR Is Required for Resistance to Vesicular Stomatitis Virus. Journal of Virology, 2000, 74, 9580-9585.	3.4	190
88	Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. British Journal of Haematology, 1998, 103, 711-715.	2.5	53
89	Dysregulation of HOX11 by Chromosome Translocations in T-cell Acute Lymphoblastic Leukemia: A Paradigm for Homeobox Gene Involvement in Human Cancer. Leukemia and Lymphoma, 1995, 16, 209-215.	1.3	26
90	Characterization of the Shope Fibroma Virus DNA Ligase Gene. Virology, 1994, 202, 642-650.	2.4	17

#	Article	IF	Citations
91	Oncolytic viruses: a step into cancer immunotherapy. Virus Adaptation and Treatment, 0, , 1.	1.5	4